SkylineDx’s Merlin Test Recognized by NCCN for Melanoma

SkylineDx’s Merlin Test Recognized by NCCN for Melanoma

By Karen Roman SkylineDx said its Merlin CP-GEP molecular test is uniquely recognized by the National Comprehensive Cancer Network (NCCN) for predictive use in select T1 and T2 melanoma patients. The test provides informed risk stratification and helps physicians better understand...

Upbound Group Q4 Revenue Up 11%, EPS Exceeds Estimates

Upbound Group Q4 Revenue Up 11%, EPS Exceeds Estimates

By Karen Roman Upbound Group, Inc. (NASDAQ: UPBD) said total revenue increased 11% in the fourth quarter of 2025 to reach $1.2 billion while earnings per share were $1.01, both metrics surpassing analysts’ estimates. Net cash by operating activities was...

Input your search keywords and press Enter.